BioSpace News Archive

Calyxt, Inc. announced that it has completed the previously announced reverse stock split of Calyxt’s common stock, par value $0.0001 per share, at a ratio of 1-for-10.

Vyant Bio, Inc. is a biotechnology company that incorporates innovative biology and data science to improve drug discovery for complex neurodevelopmental and neurodegenerative disorders.

Xerox Holdings Corporation announced the donation of the Palo Alto Research Center to SRI International, a nonprofit research institute behind some of the world’s most impactful deep tech advancements.

MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced that the Company’s management will participate in the following upcoming investor conferences.

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the first quarter ended March 31, 2023, after the market closes on Monday, May 8, 2023.

Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced new data from VLTR-557, its long-acting anti-VEGF biologic in development for durable wet age-related macular degeneration (AMD) treatment

Center for Pain Management, together with American Pain Consortium, is the first Interventional Pain clinic in the country to perform a trial of the new and first-of-its kind Spinal Cord Stimulator (SCS) called The Prospera™ Spinal Cord Stimulation System with Embrace One™ through Biotronik Neuro, Inc.

NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and reported financial results for the year ended December 31, 2022.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the first quarter of 2023 after the market close on Tuesday, May 9, 2023.

Ascentage Pharma announced that it recently received a zero-deficiency report from the GMP compliance audit of Ascentage Pharma’s Global Manufacturing Center by a Qualified Person of the European Union.